{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:56:11Z","timestamp":1789606571857,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.esmoop.2025.104496","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:44:53Z","timestamp":1742427893000},"page":"104496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["How we treat patients with metastatic uveal melanoma"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-4244","authenticated-orcid":false,"given":"E.F.","family":"Saldanha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-2996","authenticated-orcid":false,"given":"I.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Saibil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.104496_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104496_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.trecan.2021.05.005","article-title":"Metabolic alterations and therapeutic opportunities in rare forms of melanoma","volume":"7","author":"Han","year":"2021","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104496_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/s41417-022-00442-9","article-title":"Review of bi-specific therapies in uveal melanoma","volume":"29","author":"Orloff","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"21","key":"10.1016\/j.esmoop.2025.104496_bib4","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.21037\/atm-20-3700","article-title":"Publication trends of research on uveal melanoma during 2000-2020: a 20-year bibliometric study","volume":"8","author":"Xie","year":"2020","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104496_bib5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cancers11060817","article-title":"Uveal melanoma: a European network to face the many challenges of a rare cancer","volume":"11","author":"Piperno-Neumann","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.104496_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104496_bib7","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","article-title":"The genetic evolution of metastatic uveal melanoma","volume":"51","author":"Shain","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2025.104496_bib8","article-title":"Evolving management of stage IV melanoma","volume":"43","author":"Switzer","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104496_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104496_bib10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.104496_bib11","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.esmoop.2025.104496_bib12","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104496_bib15","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.esmoop.2025.104496_bib16","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104496_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-22-0028","article-title":"Redirecting polyclonal T cells against cancer with soluble T-cell receptors","volume":"29","author":"Berman","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104496_bib18","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1038\/s41467-024-53145-0","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat Commun"},{"issue":"10396","key":"10.1016\/j.esmoop.2025.104496_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.104496_bib20","doi-asserted-by":"crossref","first-page":"S679","DOI":"10.1016\/j.annonc.2023.09.2265","article-title":"1131P Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting","volume":"34","author":"Ribeiro","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104496_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104496_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104496_bib23","article-title":"Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study","volume":"8","author":"Najjar","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"21","key":"10.1016\/j.esmoop.2025.104496_bib24","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.3390\/cancers13215503","article-title":"Genetic landscape and emerging therapies in uveal melanoma","volume":"13","author":"Seedor","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104496_bib25","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41467-018-04322-5","article-title":"Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Nat Commun"},{"issue":"5-6","key":"10.1016\/j.esmoop.2025.104496_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00251-019-01108-x","article-title":"Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab","volume":"71","author":"Johansson","year":"2019","journal-title":"Immunogenetics"},{"key":"10.1016\/j.esmoop.2025.104496_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104496_bib28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-19-1223","article-title":"Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)","volume":"26","author":"Luke","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104496_bib29","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cam4.133","article-title":"Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives","volume":"2","author":"Buder","year":"2013","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104496_bib30","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.3390\/cancers12092557","article-title":"Treatment of metastatic uveal melanoma: systematic review","volume":"12","author":"Rodriguez-Vidal","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104496_bib31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104496_bib32","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jvir.2018.12.238","article-title":"03:45 PM Abstract No. 184 Safety and efficacy of microwave ablation for uveal melanoma metastatic to the liver","volume":"30","author":"Sterbis","year":"2019","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104496_bib33","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104496_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A\u00a0prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104496_bib35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2214\/AJR.14.14001","article-title":"Uveal melanoma metastatic to the liver: chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea","volume":"205","author":"Gonsalves","year":"2015","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104496_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1148\/radiol.2521081252","article-title":"High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma","volume":"252","author":"Yamamoto","year":"2009","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104496_bib37","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","article-title":"Efficacy and safety of the\u00a0melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter phase 3 study","volume":"31","author":"Zager","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104496_bib38","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2025.104496_bib39","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.22.01705","article-title":"Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial)","volume":"41","author":"Olofsson Bagge","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104496_bib40","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41416-022-02133-6","article-title":"A\u00a0phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma","volume":"128","author":"Piperno-Neumann","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.104496_bib41","first-page":"S651","volume":"34","author":"McKean","year":"2023"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104496_bib43","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T23:53:32Z","timestamp":1745538812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925003655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2059702925003655"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104496","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we treat patients with metastatic uveal melanoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104496"}}